especially for the individuals and families affected by Huntington’s disease who have long awaited new treatment options,” said Sage’s CEO, Barry Greene, in a statement. The discontinuation ...

“We are disappointed by the results ... especially for the individuals and families affected by Huntington’s disease who have long awaited new treatment options,” said Sage’s CEO, Barry Greene, in a ...